TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04021277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 uL/kg PS101
Description: 20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 uL/kg PS101
Description: 20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 uL/kg PS101
Description: 40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 uL/kg PS101
Description: 40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound activation and enhancement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound activation and enhancement
Study: NCT02900937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
Description: Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
Study: NCT02380599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Mid-thoracic spinal manipulation to T3-5 region

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Mobilization
Description: Mid-thoracic spinal mobilization to T3-5 region

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Ultrasound
Description: Sham ultrasound to T3-5 region
Study: NCT04913584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive Behavioral Therapy 9 weekly 2-hour online group CBT sessions delivered by trained lay peers.
Study: NCT02121691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk by Faith
Description: The Walk by Faith program is aimed at increasing physical activity and improving healthy eating to reduce or maintain healthy BMI among members of the churches.
Study: NCT01076530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study: NCT03331692

Intervention type: OTHER
Group type: OTHER
Intervention: monitoring of the proper level of general anesthesia
Description: The monitoring of the adequate level of general anesthesia was performed both clinically and instrumentally.

Intervention type: OTHER
Group type: OTHER
Intervention: monitoring of the proper level of general anesthesia
Description: The monitoring of the adequate level of general anesthesia was performed both clinically and instrumentally.
Study: NCT01156285

Intervention type: OTHER
Intervention: Filling in a patient questionnaire
Description: Filling in a patient questionnaire
Study: NCT01786629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUPREP Bowel Prep Kit
Description: solution for oral administration prior to colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved bowel preparation containing electrolytes
Description: solution for oral administration prior to colonoscopy
Study: NCT05514067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-Acupuncture
Description: A single application of EA at cardiac-related acupoints administered for 30 min prior to CABG surgery.
Study: NCT01565031

Intervention type: PROCEDURE
Intervention: Step-wise down-titration according to international guidelines.
Description: The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
Study: NCT01075815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human luteinizing hormone (rhLH)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant follicle-stimulating hormone (rFSH)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant follicle-stimulating hormone (rFSH)
Study: NCT00801151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolinza (vorinostat), vinorelbine
Description: Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.~Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days).~Patients may receive a maximum of 6 cycles of study medication.
Study: NCT01305837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 500 mg of methylprednisolone taken in 3 days every month
Study: NCT02185586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: laparoscopic cholecystectomy
Study: NCT01699178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate
Description: Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal testosterone gel (AndroGel)
Description: Total daily dose of T = 2.5 to 10 g of gel (25 mg to 100 mg T) QD
Study: NCT01261793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
Study: NCT04887597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: The study is composed of a single arm receiving secukinumab for the duration of 6 months.
Study: NCT00293085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines.
Study: NCT03031223

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: low-level laser therapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: low-level laser therapy
Description: low-level laser therapy
Study: NCT03522844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Participants randomized to the MBSR intervention will consist of an 8-week Mindfulness-Based Stress Reduction (MBSR) program, taught and facilitated by a trained instructor. The classes instruct participants in the theory and practice of several forms of mindfulness meditation: a body scan, breathing awareness, and mindfulness stretching exercises designed to bring awareness of the body and current experience of movement. The intervention will include a weekly class for 8 weeks and classes will be 2.5 hours in duration. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 10 mg/day; at week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.
Study: NCT01537263

Intervention type: DEVICE
Intervention: Ultrasound Perfusion Imaging
Description: Sonographic unit Phillips IU 22, 5ml SonoVue ultrasound contrast agent per examination, Duration: 1h
Study: NCT01658176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04691502
Description: PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane administered orally at 25 mg as a continuous daily dosing schedule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane administered orally at 25 mg as a continuous daily dosing schedule
Study: NCT04031534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-Miso PET scan coupled with MRI
Description: Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy
Study: NCT03988855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNV3837
Description: Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total maximum daily dose of 120 mg DNV3837. Infusions will be administered once daily for 10 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNV3837
Description: Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total maximum daily dose of 120 mg DNV3837. Infusions will be administered once daily for 10 consecutive days.
Study: NCT02848898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equistasi

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00593983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-driven intervention
Description: Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Time-matched health education
Description: Health education and standard of care treatment
Study: NCT02241980

Intervention type: OTHER
Intervention: Patient survey

Intervention type: OTHER
Intervention: Physician survey
Study: NCT00336375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Description: All treatment doses given either accompanied or not-accompanied with intake of fatty food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether-lumefantrine
Description: All treatment doses given either accompanied or not-accompanied with intake of fatty food.
Study: NCT04320472

Intervention type: OTHER
Intervention: Follow up
Description: Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)
Study: NCT03473652

Intervention type: OTHER
Group type: OTHER
Intervention: Adapted walking platform
Description: The walking sessions will be carried out on a suitable walking platform, including a connected play tablet.
Study: NCT03562117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.
Study: NCT01796834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: An 8-9 week MBSR course led by an experienced instructor in a group format. Participants learn mindfulness meditation techniques and simple yoga exercises. Subjects receive four phone support calls.
Study: NCT02954276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omexa Sublingual Sumatriptan tablet
Description: 75 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex Oral Product
Description: 100 mg
Study: NCT03867123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM561
Description: Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM561
Description: Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT
Description: In Arm 1: Fractionated focal irradiation of 1.8-2 Gy/fraction/day, 5 days/week, 6 weeks. Total dose up to 60 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)
Study: NCT01911819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus augmentation
Study: NCT00816244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
Study: NCT01399619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN/RBV for 24 or 48w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN/RBV for 24 or 48w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI201335
Description: BI201335 for 12w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI201335 24W
Description: BI201335 for 24w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN/RBV for 24 or 48w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bi 201335
Description: BI 201335 for 24 w
Study: NCT02384590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioral therapy
Description: The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience.
Study: NCT04373265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant, 100 mg soft gel capsules orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg infusion every 6 weeks
Study: NCT02497261

Intervention type: PROCEDURE
Intervention: Double-blind placebo-controlled peanut challenge
Description: Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
Study: NCT03917966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210+docetaxel+nedaplatin
Description: neoadjuvant chemotherapy:SHR-1210, 200mg,q2w, a total of 3 times; docetaxel 75mg/m2 ivgtt d1, nedaplatin 75mg/m2 ivgtt d1, q3w, for 2 cycles.The patient was evaluated after 2 cycles of neoadjuvant chemotherapy. The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210+Apatinib
Description: SHR-1210, 200 mg, q2w; Apatinib, 250mg, qd; 4 weeks is a cycle, a total of 2 cycles
Study: NCT01043809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Procter & Gamble school-based handwashing promotion program
Description: Handwashing promotion lesson and materials targeting first grade students

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: expanded school-based handwashing promotion
Description: Procter \& Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
Study: NCT03271580

Intervention type: DIAGNOSTIC_TEST
Intervention: Finger prick test for HbA1c measurement
Description: HbA1c measurement with finger prick method

Intervention type: DIAGNOSTIC_TEST
Intervention: Finger prick test for HbA1c measurement
Description: HbA1c measurement with finger prick method

Intervention type: PROCEDURE
Intervention: Punch Biopsy
Description: Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).

Intervention type: PROCEDURE
Intervention: Punch Biopsy
Description: Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).

Intervention type: OTHER
Intervention: Vac Sponge Collection
Description: NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation

Intervention type: OTHER
Intervention: Vac Sponge Collection
Description: NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
Study: NCT01911819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus augmentation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus augmentation
Study: NCT00838526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole ER
Description: 50 mg capsule, taken orally, once daily for 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 150 mg capsule, taken orally, twice daily for 26 weeks.
Study: NCT00578201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radiochemotherapy,combination Cetuximab-FOLFOX
Description: objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX
Study: NCT01522456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo Gel
Description: Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
Study: NCT01076530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT02795585

Intervention type: OTHER
Intervention: QFR (observational)
Description: QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
Study: NCT00529425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Study: NCT01652339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exforge tab. 10/160mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodivixx tab. 5/160mg
Study: NCT00038064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa will be administered 4.5 mcg/kg QW until hemoglobin correction is achieved. Subjects meeting hemoglobin criteria for correction will receive a maintenance dose of darbepoetin alfa of 4.5 mcg/kg Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHuEPO
Description: 150 IU/kg TIW
Study: NCT01911819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Equimatrix
Description: Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSSIF-i sem
Description: OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bio-oss
Description: Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
Study: NCT00246350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: massage
Description: 8 light massage treatments and hot pack
Study: NCT01522456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retin-A Micro Microsphere 0.1%
Description: Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
Study: NCT01467297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftidoren
Description: ceftidoren 200 mg bid for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: levofloxacin 500 mg once daily for 7 days
Study: NCT01400542

Intervention type: DEVICE
Intervention: CPAP Treatment
Description: Patients with obstructive sleep apnea syndrome will be treated by Continuous Positive Airway Pressure (CPAP) at home during all 4 months all nights.

Intervention type: DEVICE
Intervention: No treatment
Description: no treatment
Study: NCT02329028

Intervention type: DEVICE
Intervention: Prehospital mini-EEG
Description: Observational
Study: NCT04478929

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastroscopy
Description: Routine gastroscopy